Copiktra (Duvelisib) Patent Expiration, LOE Window & CMS Spending
Copiktra (Duvelisib) by Secura Bio: FDA Orange Book core substance LOE 2032-09-24 (last listed 2035-04-26), 0 AB generics, $36.9M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Secura Bio |
| FDA Application & Pathway | N211155 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2032-09-24 |
| Last Listed Patent or Exclusivity Date | 2035-04-26 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $36.9M |
| 2024 Medicare Part D Spend | $31.4M |
| 2024 Medicaid Spend | $5.5M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 94.0% 2-yr change) |